目的：研究人工髋关节置换术后使用低分子肝素预防深静脉血栓的安全性。
Objective: to investigate the safety of low molecular weight heparin to prevent deep venous thrombosis after primary hip replacement surgery.
方法：对比使用肝素与使用低分子肝素在血液透析中的抗凝效果，透析效果及其副作用。
Methods Compare the effect on anticoagulant therapy, hemodialysis and the side effect from the use of heparin with those from the use of Low Molecular Weight Heparins.
结论：预防性使用低分子肝素可以降低髋、膝关节置换术后dvt的发生，不良反应发生率低。
Conclusion: low molecular weight heparin can reduce the incidence of DVT after hip or knee replacements with a low incidence of side effect.
病人诊断为左下肢DVT，并使用低分子肝素（那曲肝素0·4mL，一日两次）持续治疗两周。
The patient was diagnosed with DVT of the left leg, and low-molecular-weight heparin (nadroparin 0·4 mL, two times per day) was started, lasting 2 weeks.
《国际循环》：对ACS患者通常你会选择使用哪种低分子量肝素？
International Circulation: Which LMWH would you normally choose to use in ACS patients?
结论使用肠溶阿司匹林和低分子肝素钙联合治疗急性脑梗塞疗效好，使用简便、安全、经济，可在临床予推广应用。
Conclusion it is quite effective, convenient, safe, economical and commendatory to use aspirin and low molecular weight heparin in acute cerebral infarction therapy.
结论：维甲酸、化疗、低分子肝素合用治疗急性早幼粒细胞性白血病并dic疗效明显，值得临床推广使用。
Conclusion: All-trans tretinoin acid chemotherapy in combination with low dosage heparin in the treatment of APL with DIC can obtain obvious effect.
结论每一个低分子肝素产品间都存在着明显的差异，具有不同的特点，临床使用中应按指征个体化给药。
CONCLUSION Every low molecule heparin product has its own feature, and they should be used individualized in clinic.
结论每一个低分子肝素产品间都存在着明显的差异，具有不同的特点，临床使用中应按指征个体化给药。
CONCLUSION Every low molecule heparin product has its own feature, and they should be used individualized in clinic.
应用推荐